More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.
X Biopharma Ltd. (SG:42C) has released an update. iX Biopharma Ltd. announced that its novel semaglutide sublingual wafer, iXB 401, achieved 20 ...